- Home
- STAI vs CMMB Comparison
STAI vs CMMB Comparison
Compare STAI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- CMMB
- Stock Information
- Founded
- STAI 2011
- CMMB 2004
- Country
- STAI United States
- CMMB Israel
- Employees
- STAI N/A
- CMMB N/A
- Industry
- STAI
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- CMMB Health Care
- Exchange
- STAI Nasdaq
- CMMB Nasdaq
- Market Cap
- STAI 24.7M
- CMMB 23.0M
- IPO Year
- STAI N/A
- CMMB N/A
- Fundamental
- Price
- STAI $0.73
- CMMB $1.32
- Analyst Decision
- STAI
- CMMB Strong Buy
- Analyst Count
- STAI 0
- CMMB 2
- Target Price
- STAI N/A
- CMMB $8.50
- AVG Volume (30 Days)
- STAI 970.9K
- CMMB 109.4K
- Earning Date
- STAI 01-01-0001
- CMMB 05-15-2025
- Dividend Yield
- STAI N/A
- CMMB N/A
- EPS Growth
- STAI N/A
- CMMB N/A
- EPS
- STAI N/A
- CMMB N/A
- Revenue
- STAI $542,166.00
- CMMB N/A
- Revenue This Year
- STAI N/A
- CMMB N/A
- Revenue Next Year
- STAI N/A
- CMMB N/A
- P/E Ratio
- STAI N/A
- CMMB N/A
- Revenue Growth
- STAI N/A
- CMMB N/A
- 52 Week Low
- STAI $0.70
- CMMB $0.78
- 52 Week High
- STAI $9.07
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- STAI N/A
- CMMB 50.69
- Support Level
- STAI N/A
- CMMB $1.31
- Resistance Level
- STAI N/A
- CMMB $1.44
- Average True Range (ATR)
- STAI 0.00
- CMMB 0.08
- MACD
- STAI 0.00
- CMMB 0.00
- Stochastic Oscillator
- STAI 0.00
- CMMB 54.55
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.